Literature DB >> 21968241

Th17 cells in Behçet's disease: a new immunoregulatory axis.

Kamel Hamzaoui1.   

Abstract

Accumulating evidence suggests that the abnormality of innate and adaptive immunity responses plays an important role in Behçet's disease (BD). T helper (Th) cells have a central role in modulating immune responses. Traditionally, BD is regarded as a Th1-mediated inflammatory disease. Recently, Th17 cells were identified as a new subset of Th cells unrelated to Th1 or Th2 cells, and several cytokines are involved in regulating their activation and differentiation. Naïve murine CD4+ Th can be induced to differentiate towards Th1, Th2, Th17 and Treg phenotypes according to the local cytokine milieu. The committed cells are characterised by expression of specific transcription factors, T bet for Th1, GATA-3 for Th2, Foxp3 for Tregs and RORγt (RORγt/RORC) for Th17 cells. It has been demonstrated that the skewing of murine Th towards Th17 and Treg is mutually exclusive. Th17 cells regulate inflammation via production of distinct cytokines such as interleukin (IL)-17. There is growing evidence that Th17 cells are pathological in many human autoimmune and inflammatory diseases, leading to intense interest in defining their origins, functions and developing strategies to block their pathological effects. Evidence from human disease such as BD suggests that specialised antigen-presenting cells drive their in vivo development. Knowledge of how Th17 cells interact with other immune cells is limited, but recent data suggest that Th17 cells may not be subject to strict cellular regulation by T regulatory cells. Notably, Th17 cells and Treg cells appear to share common developmental pathways and both cell types retain significant plasticity. Herein, we will discuss the molecular and cellular regulation of Th17 cells with an emphasis on BD. The identification of Th17 cells helps us to explain some of the anomalies seen in the Th1/Th2 axis and has broadened our understanding of the immunopathological effects of Th17 cells in the development of BD.

Entities:  

Mesh:

Year:  2011        PMID: 21968241

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  25 in total

1.  [Update: Behçet's disease].

Authors:  I Kötter
Journal:  Z Rheumatol       Date:  2012-11       Impact factor: 1.372

2.  Identification of possible pathogenic pathways in Behçet's disease using genome-wide association study data from two different populations.

Authors:  Burcu Bakir-Gungor; Elaine F Remmers; Akira Meguro; Nobuhisa Mizuki; Daniel L Kastner; Ahmet Gul; Osman U Sezerman
Journal:  Eur J Hum Genet       Date:  2014-09-17       Impact factor: 4.246

3.  Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis.

Authors:  Marta Consuegra-Fernández; Marc Julià; Mario Martínez-Florensa; Fernando Aranda; Cristina Català; Noelia Armiger-Borràs; María-Teresa Arias; Francisca Santiago; Antonio Guilabert; Anna Esteve; Carlos Muñoz; Carlos Ferrándiz; José-Manuel Carrascosa; Edurne Pedrosa; Jorge Romaní; Mercè Alsina; José-Manuel Mascaró-Galy; Francisco Lozano
Journal:  Cell Mol Immunol       Date:  2017-12-11       Impact factor: 11.530

4.  New approaches in immunotherapy of behçet disease.

Authors:  Fatemeh Zare Shahneh; Mozhdeh Mohammadian; Zohreh Babaloo; Behzad Baradaran
Journal:  Adv Pharm Bull       Date:  2013-02-07

Review 5.  Behçet syndrome: from pathogenesis to novel therapies.

Authors:  Gianluigi Mazzoccoli; Angela Matarangolo; Rosa Rubino; Michele Inglese; Angelo De Cata
Journal:  Clin Exp Med       Date:  2014-12-02       Impact factor: 3.984

6.  Activation of the JAK/STAT pathway in Behcet's disease.

Authors:  A Tulunay; M G Dozmorov; F Ture-Ozdemir; V Yilmaz; E Eksioglu-Demiralp; F Alibaz-Oner; G Ozen; J D Wren; G Saruhan-Direskeneli; A H Sawalha; H Direskeneli
Journal:  Genes Immun       Date:  2014-11-20       Impact factor: 2.676

7.  Activation of the aryl hydrocarbon receptor affects activation and function of human monocyte-derived dendritic cells.

Authors:  C Wang; Z Ye; A Kijlstra; Y Zhou; P Yang
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

Review 8.  Diagnostic approach and current treatment options in childhood vasculitis.

Authors:  Kenan Barut; Sezgin Şahin; Amra Adroviç; Özgür Kasapçopur
Journal:  Turk Pediatri Ars       Date:  2015-12-01

9.  Influence of corticosteroid therapy on IL-18 and nitric oxide production during Behçet's disease.

Authors:  Fatmazohra Djaballah-Ider; Zineb Djeraba; Mourad Chemli; Nadjiba Dammene-Debbihe; Doulkifly Lounis; Houda Belguendouz; Yanis Medour; Samia Chaib; Chafia Touil-Boukoffa
Journal:  Inflammopharmacology       Date:  2018-03-29       Impact factor: 4.473

Review 10.  Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab.

Authors:  Francesco Caso; Luca Iaccarino; Silvano Bettio; Francesca Ometto; Luisa Costa; Leonardo Punzi; Andrea Doria
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.